ScripsAmerica Enters Agreement With DPG Distribution for the Exclusive Representation of RapiMed(R) Throughout North America

ScripsAmerica Enters Agreement With DPG Distribution for the Exclusive
Representation of RapiMed(R) Throughout North America

LANGHORNE, Pa., June 26, 2013 (GLOBE NEWSWIRE) -- ScripsAmerica Inc.
(OTCBB:SCRC), a supplier of prescription, OTC and nutraceutical drugs, today
announced that the Company has entered into a Representation Agreement with
DPG Distribution ("DPG") for the exclusive right to purchase, promote and
resell its RapiMed® OTC products throughout North America, commencing with its
children's pain reliever and fever reducer.

The Agreement has a term of two years and contains a provision whereby its
exclusivity is subject to DPG meeting designated sales quotas for RapiMed®.
DPG Distribution offers worldwide sales, marketing and distribution services
for high-end retail consumer products. The company calls on some of the
largest retail chains in the world such as Wal-Mart, Costco, Target,
Walgreens, CVS and ShopRite.

ScripsAmerica's CEO, Bob Schneiderman, commented, "ScripsAmerica is extremely
proud and pleased to announce this agreement, which we believe has tremendous
growth implications for our company and its shareholders. DPG Distribution's
network of clients is not only tremendous in size and quality, but it contains
some of the world's largest retailers who are at the pinnacle of our target
market."

"By working with DPG, ScripsAmerica is now able to maximize our large-scale
national market opportunities for RapiMed® Children's Pain Reliever and Fever
Reducer. We expect this development to have a profound and positive impact on
the success of RapiMed®'s product launch as well as its ongoing sales and
market penetration," continued Schneiderman.

Gordon Jones, Chief Operating Officer of DPG Distribution, added, "DPG is very
excited to represent RapiMed® in the North American market. RapiMed® has the
potential to experience great success penetrating the massive market for
children's pain relievers because of its speed, effectiveness, dosing accuracy
and safety. Currently, we believe a very large opportunity exists for a new,
superior product like RapiMed® to be introduced and capture significant market
share. DPG looks forward to a long and profitable partnership with
ScripsAmerica."

ScripsAmerica anticipates launching its RapiMed® product in September of this
year into retail, food and drug store chains with plans to expand its
distribution avenues.

About DPG Distribution

DPG Distribution is a distributor of high-end retail consumer products,
offering worldwide service in sales, marketing, distribution and in-store
support in all significant channels including academic, state and federal
government, military, large to small consumer retailers, online merchants and
rent to own channels. Initially focused on North America, DPG is now expanding
its business to Latin and South America as well as Europe. For more
information, visit www.dpgdistribution.com.

About ScripsAmerica, Inc.

ScripsAmerica, Inc. delivers pharmaceutical products to a wide range of end
users across the health care industry through the largest pharmaceutical
distributor in North America, McKesson Corporation. End users include retail
pharmacies, hospitals, long-term care facilities and government and home care
agencies.

For more information, visit www.ScripsAmerica.com.

Safe Harbor Statement

This release includes forward-looking statements, which are based on certain
assumptions and reflects management's current expectations. These
forward-looking statements are subject to a number of risks and uncertainties
that could cause actual results or events to differ materially from current
expectations. Some of these factors include: general global economic
conditions; general industry and market conditions, sector changes and growth
rates; uncertainty as to whether our strategies and business plans will yield
the expected benefits; increasing competition; availability and cost of
capital; the ability to identify and develop and achieve commercial success;
the level of expenditures necessary to maintain and improve the quality of
services; changes in the economy; changes in laws and regulations, including
codes and standards, intellectual property rights, and tax matters; or other
matters not anticipated; our ability to secure and maintain strategic
relationships and distribution agreements. The Company disclaims any intention
or obligation to update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise.

CONTACT: 888-959-7095
 
Press spacebar to pause and continue. Press esc to stop.